Cancer drug resistance induced by EMT: novel therapeutic strategies

Area of Science:

• Oncology
• Cancer Biology
• Molecular Medicine

Background:

• Drug-targeting strategies have improved cancer therapy, but drug resistance remains a significant clinical problem.
• Epithelial-mesenchymal plasticity (EMP) and the tumor microenvironment are implicated as factors limiting treatment efficacy.
• Epithelial-to-mesenchymal transition (EMT) is linked to therapy resistance in preclinical models, yet clinical evidence is limited.

Purpose of the Study:

• To review the mechanisms by which intermediate epithelial/mesenchymal (E/M) states and microenvironment interactions contribute to therapy resistance.
• To explore the role of bioinformatics and pharmacogenomics in understanding EMT's impact on drug resistance.
• To identify potential novel pharmacological strategies for overcoming EMT-driven drug resistance.

Main Methods:

• Literature review focusing on mechanisms of intermediate E/M states and microenvironment influence.
• Analysis of existing preclinical and clinical data on EMT and therapy resistance.
• Discussion of the application of bioinformatics and pharmacogenomics in cancer drug resistance research.

Main Results:

• Intermediate E/M states, influenced by the tumor microenvironment, play a crucial role in mediating therapy resistance.
• Limited clinical data currently supports the extensive preclinical findings on EMT and drug resistance.
• Bioinformatics and pharmacogenomics offer promising avenues for elucidating EMT's biological impact and developing new therapies.

Conclusions:

• Understanding the interplay between intermediate E/M states, microenvironment, and drug resistance is critical for advancing cancer treatment.
• Further clinical validation is needed to confirm the role of EMT in therapy resistance.
• Integrating bioinformatics and pharmacogenomics can pave the way for innovative pharmacological interventions against drug-resistant cancers.